Axis Mutual FundEquity Schemes - Focused Fund13.8 years
The scheme seeks to generate long term capital appreciation by investing in concentrated portfolio of equity & equity related instruments of upto 25 companies, primarily in companies among the top 200 in terms of market capitalisation.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Three-year return sits below the 25th percentile of comparable share classes.
Prefer peers if · Prefer Canara Robeco Focused Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.01% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -33.7%. Ask whether you can hold through a similar fall.
Vs category
Watch
46% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Krishnaa Narayan · 2.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Watch
Top 10 holdings ≈ 57.9% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 34%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY 500 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
12 Feb 2020 – 10 Nov 2020
Trough 23 Mar 2020 · recovered in 232 days
-33.7%
14 Oct 2021 – 28 Mar 2024
Trough 17 Jun 2022 · recovered in 650 days
-28.3%
7 Aug 2015 – 11 Jul 2016
Trough 25 Feb 2016 · recovered in 137 days
-19.5%
23 Sept 2024 – 12 Aug 2026
Trough 30 Mar 2026 · recovered in 135 days
-18.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
22
Vs category
56
Consistency
41
Risk-adjusted
49
Drawdown
16
Mean
37
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
No supporting reads in the current evidence set.
30 Sept 2026 · 29 holdings · top 10 are 57.9%.
ICICI Bank Ltd
Financial
8.1%
Zomato Ltd
Technology
7.8%
Divi's Laboratories Ltd
Healthcare
6.5%
Others CBLO
Unspecified
6.2%
Bajaj Finance Ltd
Financial
5.3%
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Canara Robeco Mutual Fund
Invesco Mutual Fund
Mahindra Manulife Mutual Fund
ICICI Prudential Mutual Fund
Caveat: Deeper drawdown · Higher TER
HSBC Mutual Fund
Caveat: Higher TER
Axis Mutual FundEquity Schemes - Focused Fund13.8 years
The scheme seeks to generate long term capital appreciation by investing in concentrated portfolio of equity & equity related instruments of upto 25 companies, primarily in companies among the top 200 in terms of market capitalisation.
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 29 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Three-year return sits below the 25th percentile of comparable share classes.
Prefer peers if · Prefer Canara Robeco Focused Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
13.8 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
1.01% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -33.7%. Ask whether you can hold through a similar fall.
Vs category
Watch
46% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Krishnaa Narayan · 2.7 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Watch
Top 10 holdings ≈ 57.9% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 34%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
29 Oct 2026 · -5.7% over 1Y
61.95
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Date-aligned against NIFTY 500 TRI. Capture ratios use common month-end observations through 30 Oct 2026.
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
29 Oct 2026
-7.5%
12 Feb 2020 – 10 Nov 2020
Trough 23 Mar 2020 · recovered in 232 days
-33.7%
14 Oct 2021 – 28 Mar 2024
Trough 17 Jun 2022 · recovered in 650 days
-28.3%
7 Aug 2015 – 11 Jul 2016
Trough 25 Feb 2016 · recovered in 137 days
-19.5%
23 Sept 2024 – 12 Aug 2026
Trough 30 Mar 2026 · recovered in 135 days
-18.2%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
22
Vs category
56
Consistency
41
Risk-adjusted
49
Drawdown
16
Mean
37
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
No supporting reads in the current evidence set.
30 Sept 2026 · 29 holdings · top 10 are 57.9%.
ICICI Bank Ltd
Financial
8.1%
Zomato Ltd
Technology
7.8%
Divi's Laboratories Ltd
Healthcare
6.5%
Others CBLO
Unspecified
6.2%
Bajaj Finance Ltd
Financial
5.3%